Emerging Trends to Drive Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Growth at 13.5% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for the treatment of primary progressive multiple sclerosis (ppms) has seen significant expansion in recent years. It is set to increase from $1.02 billion in 2024 to $1.16 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.7%. The escalation in the historical phase can be credited to a rising incidence of PPMS in the elderly population, improved understanding of PPMS among both patients and medical professionals, increasing investment in PPMS therapy research and development, a growing use of disease-modifying therapies (DMTs), and broadening government programs and funding for innovative PPMS treatments.

How Will the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size Evolve and Grow by 2029?
The market size for the treatment of primary progressive multiple sclerosis (ppms) is projected to experience significant growth in the upcoming years. By 2029, it's forecasted to reach a size of $1.92 billion with a compound annual growth rate (CAGR) of 13.5%. The expansion in this forecast period is likely due to a rise in clinical trials for innovative PPMS medications, improvements in diagnostic procedures, an increased demand for tailor-made and targeted medicines, developing healthcare facilities, and a rise in collaborations and partnerships within the pharmaceutical sector. Key trends predicted for this period include development in therapies aimed at slowing PPMS progression, incorporation of biomarker research for custom treatment plans, technology-based enhancements in MRI and other diagnostic imaging methods, progress in research for neuroprotective and remyelination drugs, and advancements in using genetic and molecular profiling for patient categorization.

View the full report here:
https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

What Drivers Are Propelling the Growth of Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Forward?
The escalating need for efficacious remedies is anticipated to boost the expansion of the primary progressive multiple sclerosis (PPMS) treatment market in the future. Efficacious remedies entail medical actions that alleviate symptoms, enhance patient outcomes, or cure ailments or conditions. The escalating need is primarily fueled by the increasing occurrence of chronic and intricate health complications that necessitate long-term management and advanced therapeutic interventions to boost patient outcomes and life quality. Efficacious remedies support the deceleration of primary progressive multiple sclerosis (PPMS) by targeting inflammation and maintaining neurological function, thereby enhancing long-term life quality, minimizing disability accumulation, and boosting patients' capacity to control daily tasks with enhanced independence and stability. For example, in January 2024, as per the American Society of Gene & Cell Therapy, a U.S-based gene and cell therapy organization, the number of gene therapies in Phase III clinical trials escalated to 33 Phase III gene therapy trials in 2023, marking a growth of 10% in comparison to 2022. This marked the first quarterly growth since Q3 2022. Hence, the escalating need for efficacious remedies propels the expansion of the primary progressive multiple sclerosis (PPMS) treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

Which Emerging Trends Are Transforming the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market in 2025?
Major firms in the primary progressive multiple sclerosis (PPMS) treatment sphere are placing emphasis on developing groundbreaking formulas like monoclonal antibody medications to improve the management of multiple sclerosis. These drugs function by zeroing in on certain immune cells or proteins that provoke inflammation and harm the nervous system, thereby diminishing disease activity and decelerating symptom progression. For instance, in February 2024, India's Roche Pharma announced the launch of Ocrevus (ocrelizumab), a monoclonal antibody-based drug designed to address multiple sclerosis in the Indian market. Ocrevus stands out for being the first and only authorized disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) within the country. The drug impedes the function of CD20-positive B cells - a type of immune cell implicated in the irregular immune response associated with MS. The drug is given twice annually as a two-hour intravenous infusion, offering a more efficient and manageable treatment scheme for patients.

What Are the Key Segments in the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
The primary progressive multiple sclerosis (PPMS) treatment market covered in this report is segmented -

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone
4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp

Who Are the Key Players Shaping the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market's Competitive Landscape?
Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are F. Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, Brainstorm Cell Therapeutics Inc.

What Geographic Markets Are Powering Growth in the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (PPMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24670

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.